As the pursue of better patient healthcare continues, medical centers seek novel innovative technologies that can help reduce errors and increase standardization, leading ultimately to best treatment decisions for each patient.
Current patient diagnosis processes fail to identify all biomarkers, most are not tested in the standard of care. This is due to the dependence on adequate tissue to deliver conclusive results, and the costly and cumbersome process involved.
lmagene's solution detects, with high sensitivity and specificity, a broad range of biomarkers, enabling a better diagnosis for cancer patients and providing real-time identification of candidates for clinical trials and for targeted cancer therapy, and all of this using a biopsy image only
